Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790503 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase 1 study of Patients With Newly Diagnosed Glioblastoma, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 9
- Study locations
NCT01790503 is a Phase 1 study of Patients With Newly Diagnosed Glioblastoma that has completed, run by Daiichi Sankyo. The registered enrollment target is 65 participants. The trial reports 9 study locations across 7 states.
The verdict
NCT01790503, a Phase 1 study of Patients With Newly Diagnosed Glioblastoma, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 9
- Study locations
Study Summary
The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed glioblastoma (GBM).
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Temozolomide
- DRUG PLX3397
Study Locations (9)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Illinois
- Northwestern Memorial Hospital - Chicago
Michigan
- Henry Ford Hospital - Detroit
New York
- Columbia University Medical Center - New York
Ohio
- James Cancer Hospital/Ohio State University - Columbia
Utah
- Huntsman Cancer Institute University of Utah - Salt Lake City
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2013-07-18 |
| Est. Completion | 2020-03-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01790503
The ClinicalTrials.gov registry entry for NCT01790503 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Patients With Newly Diagnosed Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT01790503 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Massachusetts, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT01790503 about?
NCT01790503 is a clinical study titled "A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma". The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed glioblastoma (GBM).
What is the current status of trial NCT01790503?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2013-07-18. Estimated completion is 2020-03-04.
What conditions does trial NCT01790503 study?
This clinical trial studies the following conditions: Patients With Newly Diagnosed Glioblastoma.
What interventions are being tested in trial NCT01790503?
The interventions under investigation include: Radiation Therapy (RADIATION), Temozolomide (DRUG), PLX3397 (DRUG).
Who is sponsoring clinical trial NCT01790503?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01790503 being conducted?
This trial has 9 study locations across Illinois, Massachusetts, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.